Scripps Method May Enable Commercial-Scale Manufacture of iPSCs

The advance could also benefit stem cell companies Fate Therapeutics and Stemgent, which provide iPSCs as research and drug-discovery tools to pharmaceutical and biotech companies.

Full-text access for registered users only. Existing users login here.
New to GenomeWeb? Register quickly here for free access.